Some studies have reported that NRF2 activation inhibits LXRα activity and LXRα-dependent liver steatosis through the farnesoid X receptor (FXR)- small heterodimer partner (SHP) signaling pathway. The gene discussed is NR1H4; the disease is Hepatic steatosis.